Bioretec Ltd Considers Rights Issue to Strengthen Capital and Support New Strategy

Bioretec Ltd's Potential Rights Issue

In a recent announcement, Bioretec Ltd, a pioneering Finnish medical device company specializing in biodegradable implants, revealed that its Board of Directors is exploring the possibility of a rights issue. This move is aimed at bolstering the company's financial resources to support its newly updated strategic objectives.

Understanding the Rights Issue

The contemplated rights issue, which would grant existing shareholders a pre-emptive subscription right, is expected to generate approximately EUR 15 million. This financial boost is crucial for enabling Bioretec to execute its new corporate strategy effectively. However, it's important to note that the Board has yet to make any final commitments regarding this issue, highlighting that the decision is still under consideration.

Strategic Goals and Financial Context

Bioretec's updated strategy was outlined in a company release dated December 16, 2025. By integrating this potential rights issue, the company seeks to reinforce its capital base and ensure its financing capabilities align with its growing operational demands. The future decisions regarding the rights issue will depend on several factors, including authorization from a general shareholders' meeting and further deliberations by the Board.

Role of DNB Carnegie Investment Bank

To facilitate the rights issue's assessment, Bioretec has appointed DNB Carnegie Investment Bank AB, Finland Branch. This bank will scrutinize the proposed structure and terms of the offering, ensuring that the company's strategy moves forward with clear financial backing and market support.

Bioretec’s Innovations in Orthopedic Care

Bioretec is recognized as a leader in transforming orthopedic treatment through its innovative fully biodegradable implant technologies. The company is committed to enhancing bone growth and improving fracture healing following surgeries. Among its notable products is the RemeOs™ line, which utilizes advanced magnesium alloy and hybrid composites, presenting a new generation of strong, absorbable materials for improved surgical results.

These RemeOs implants are designed to be gradually absorbed by the body, which eliminates the need for additional surgeries to remove implants, making recovery smoother for patients. In March 2023, the first product was granted authorization for the U.S. market, while CE mark approval in Europe was achieved in January 2025.

Moreover, Bioretec's Activa product line comprises fully bioabsorbable orthopedic implants made from a proprietary self-reinforced poly(lactic-co-glycolic acid) (PLGA) material. This line is already CE marked and approved by the FDA for various indications in both adult and pediatric populations.

Future Directions

As Bioretec continues to focus its efforts on healing through absorption, it aims not only to enhance surgical outcomes but also to pave the way for more efficient and patient-friendly treatment solutions. The impending rights issue, if executed, will play a pivotal role in securing the necessary capital to realize these ambitious goals.

For further information about Bioretec and its cutting-edge technologies, visit www.bioretec.com.